Sugi Predict

Sugi Predict / Targets / SSTR3

SSTR3

Somatostatin receptor type 3 · P32745 · SSTR3 on Sugi Atlas →

30,397 patent compounds predicted against SSTR3, 18,976 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL901932 SCHEMBL901932 0.80 20/20
SCHEMBL1244095 SCHEMBL1244095 0.70 20/20
SCHEMBL1714366 SCHEMBL1714366 0.64 20/20
SCHEMBL1715602 SCHEMBL1715602 0.64 20/20
SCHEMBL823850 SCHEMBL823850 0.59 20/20
SCHEMBL825046 SCHEMBL825046 0.35 12/20
Depreotide Depreotide (SCHEMBL456503) 0.79 11/20
Somatostatin Receptor Ligand Somatostatin Receptor Ligand (SCHEMBL1163712) 0.79 11/20
Somatostatin Receptor Ligand Somatostatin Receptor Ligand (SCHEMBL670990) 0.60 11/20
Seglitide Seglitide (SCHEMBL151244) 0.56 11/20
Somatostatin Receptor Ligand Somatostatin Receptor Ligand (SCHEMBL8482) 0.83 10/20
Somatostatin Receptor Ligand Somatostatin Receptor Ligand (SCHEMBL1784775) 0.81 10/20
Somatostatin Receptor Ligand Somatostatin Receptor Ligand (SCHEMBL1164024) 0.78 10/20
Somatostatin Receptor Ligand Somatostatin Receptor Ligand (SCHEMBL1164198) 0.69 10/20
Seglitide Seglitide (SCHEMBL242685) 0.56 10/20
Somatostatin Receptor Ligand Somatostatin Receptor Ligand (SCHEMBL1845792) 0.72 9/20
Somatostatin Receptor Ligand Somatostatin Receptor Ligand (SCHEMBL1237935) 0.65 9/20
SCHEMBL108594 SCHEMBL108594 0.47 9/20
SCHEMBL139478 SCHEMBL139478 0.47 9/20
Lanreotide Lanreotide (SCHEMBL1649219) 0.98 8/20

Clinical trials — most relevant to SSTR3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy PHASE3RECRUITING
PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial) PHASE3RECRUITING
Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer PHASE3RECRUITING
Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide PHASE1/PHASE2RECRUITING
Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression PHASE2UNKNOWN
Pasireotide LAR in Severe Polycystic Liver Disease PHASE2COMPLETED
Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer PHASE2COMPLETED
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) PHASE2COMPLETED
61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET) PHASE1/PHASE2RECRUITING
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors PHASE1/PHASE2RECRUITING
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours PHASE2RECRUITING
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors PHASE1/PHASE2RECRUITING
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT PHASE2COMPLETED
Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor PHASE2RECRUITING
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors PHASE1/PHASE2COMPLETED
An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours PHASE2UNKNOWN
Dosimetry Guided PRRT With 90Y-DOTATOC PHASE2WITHDRAWN
Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer PHASE2COMPLETED
Evaluation of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors PHASE1/PHASE2COMPLETED
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake PHASE2RECRUITING
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents PHASE1/PHASE2WITHDRAWN
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors PHASE1RECRUITING
Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms EARLY_PHASE1COMPLETED
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors EARLY_PHASE1ACTIVE_NOT_RECRUITING
Molecular and Whole-body MR Imaging in Lymphomas nanCOMPLETED
Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia nanNO_LONGER_AVAILABLE
Observational Study on GEP-and Pulm-NET Treated at FPG nanRECRUITING
Somatostatin Receptor PET/CT in SSTR-Related Disease Patients nanRECRUITING
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx nanAPPROVED_FOR_MARKETING
Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT) nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SSTR3 binder may also engage these)

ProteinNameSimilarity
P30936 — 0.996 P30936 →
P30935 — 0.996 P30935 →
P49660 — 0.988 P49660 →
P30937 — 0.980 P30937 →
SSTR4 Somatostatin receptor type 4 0.979 landscape →
NPFFR1 Neuropeptide FF receptor 1 0.971 landscape →
SSTR5 Somatostatin receptor type 5 0.968 landscape →
O97661 — 0.966 O97661 →
HCRTR1 Orexin/Hypocretin receptor type 1 0.966 landscape →
Q49LX5 — 0.964 Q49LX5 →
Q56UD9 — 0.963 Q56UD9 →
Q0GBZ5 — 0.963 Q0GBZ5 →
P49681 — 0.963 P49681 →
Q8HYC3 — 0.963 Q8HYC3 →
Q9EP86 — 0.963 Q9EP86 →
P48146 — 0.963 P48146 →
SSTR1 Somatostatin receptor type 1 0.963 landscape →
GALR2 Galanin receptor type 2 0.961 landscape →
NPBWR1 Neuropeptides B/W receptor type 1 0.960 landscape →
Q8MJV3 — 0.960 Q8MJV3 →
GALR3 Galanin receptor type 3 0.959 landscape →
Q8MJV2 — 0.959 Q8MJV2 →
O08726 — 0.958 O08726 →
P28646 — 0.958 P28646 →
P56718 — 0.958 P56718 →
P30873 — 0.958 P30873 →
P58307 — 0.956 P58307 →
P30938 — 0.956 P30938 →
P49220 — 0.956 P49220 →
UTS2R Urotensin-2 receptor 0.955 landscape →